abrdn Life Sciences Investors Shares of Beneficial Interest (HQL)
EBITDA Margin
135.93%
Quarterly · Period ending:
HQL EBITDA Margin
Latest reported135.93%period ending
Latest reported135.93%period ending
HQL Quarterly EBITDA Margin (5192.86% → 135.93%)
Quarterly ebitda margin
High-resolution chart · PNG
HQL ebitda margin history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Margin |
|---|---|
| 135.9267% | |
| 1,141.7645% | |
| -251.9903% | |
| 1,830.0333% | |
| 4,898.4645% | |
| -34.5453% | |
| 0% | |
| -124.4969% | |
| -733.5323% | |
| 219.5917% | |
| 115.649% | |
| 572.9106% | |
| 135.8027% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| -0.1265% | |
| -0.1386% | |
| 0.1397% | |
| -0.1198% | |
| 0% | |
| 0% | |
| -0.215% | |
| 21,727.3847% | |
| 11,497.2233% | |
| 1,621.4226% | |
| 8,050.956% | |
| 6,573.6842% | |
| 6,573.6842% | |
| 559.8901% | |
| 559.8901% | |
| -684.7826% | |
| -684.7826% | |
| 3,607.7844% | |
| 3,607.7844% | |
| 1,753.8194% | |
| 1,753.8194% | |
| -58.2609% | |
| -58.2609% | |
| 5,029.2135% | |
| 5,029.2135% | |
| 2,237.5% | |
| 2,237.5% | |
| 6,331.1475% | |
| 6,331.1475% | |
| -268.0851% | |
| -268.0851% | |
| -109.6045% | |
| -109.6045% | |
| -1,250% | |
| -1,250% | |
| 4,746.875% | |
| 4,746.875% | |
| 5,192.8571% | |
| 5,192.8571% |